MGTA

Magenta Therapeutics, Inc. [MGTA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MGTA Stock Summary

In the News

10:49 28 Mar 2024 MGTA

10 Best-Performing Penny Stocks in the Health Care Sector

The healthcare sector has more high return generating companies than many other sectors.

09:54 28 Mar 2024 MGTA

Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks

Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).

12:21 28 Mar 2024 MGTA

MGTA Stock: 51.66% Surge Explained

The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why.

09:02 28 Mar 2024 MGTA

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.

03:35 28 Mar 2024 MGTA

Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%

The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why.

08:00 28 Mar 2024 MGTA

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

11:17 28 Mar 2024 MGTA

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

12:23 28 Mar 2024 MGTA

Magenta Therapeutics Trims R&D, Cuts Workforce

Magenta Therapeutics Inc (NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research.

06:20 28 Mar 2024 MGTA

Big Pharma Is Going Holiday Shopping. Who's Next?

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

06:06 28 Mar 2024 MGTA

Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high of 22 out of 37 weeks this year in negative conditions above the 40 MG level.

MGTA Financial details

Company Rating
Neutral
Market Cap
42.44M
Income
-67.32M
Revenue
0
Book val./share
45.66
Cash/share
48.6
Dividend
-
Dividend %
-
Employees
67
Optionable
No
Shortable
Yes
Earnings
01 Nov 2023
P/E
-0.61
Forward P/E
-
PEG
0.61
P/S
-
P/B
0.57
P/C
-
P/FCF
-0.58
Quick Ratio
19.23
Current Ratio
19.49
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-20.4
EPS next Y
-
EPS next Q
-
EPS this Y
1.68%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
266.99%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
47.38%
Inst Trans
0.98%
ROA
-89%
ROE
-73%
ROC
-0.57%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
60.66M
Shs Float
33.64M
-
-
-
-
Target Price
-
52W Range
0.321-1.81
52W High
-
52W Low
-
RSI
-
Rel Volume
1.52
Avg Volume
247.98K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.11411
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

MGTA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-59.42-35.28-29.93-22.67-23.05
Operating cash flow per share
-43.28-29.31-27.7-20.58-21.47
Free cash flow per share
-51.2-30.88-27.87-21.02-21.57
Cash per share
147.374.864.3961.1835.85
Book value per share
150.4872.4862.2559.7133.91
Tangible book value per share
150.4872.4862.2559.7133.91
Share holders equity per share
150.4872.4862.2559.7133.91
Interest debt per share
00008.17
Market cap
5.52M29.53M18.12M12.81M1.23M
Enterprise value
-52.83M-35.54M-40.03M-118.84M-26.43M
P/E ratio
-0.1-0.43-0.26-0.2-0.02
Price to sales ratio
00000
POCF ratio
-0.13-0.52-0.28-0.22-0.02
PFCF ratio
-0.11-0.49-0.28-0.21-0.02
P/B Ratio
0.040.210.130.070.01
PTB ratio
0.040.210.130.070.01
EV to sales
00000
Enterprise value over EBITDA
0.880.430.511.590.33
EV to operating cash flow
1.260.620.6320.39
EV to free cash flow
1.070.590.621.950.39
Earnings yield
-10.43-2.33-3.82-5.12-58.35
Free cash flow yield
-8.98-2.04-3.55-4.75-54.61
Debt to equity
00000.28
Debt to assets
00000.2
Net debt to EBITDA
0.970.780.741.760.35
Current ratio
13.9510.6213.2616.297.95
Interest coverage
000018.22
Income quality
0.730.740.850.840.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.180.050.010.020
Capex to revenue
00000
Capex to depreciation
-8.77-1.66-0.2-0.63-0.16
Stock based compensation to revenue
00000
Graham number
448.56239.85204.76174.51132.61
ROIC
-0.43-0.53-0.5-0.4-0.46
Return on tangible assets
-0.37-0.43-0.43-0.35-0.49
Graham Net
135.2564.3756.7255.2122.83
Working capital
134.9M135.73M140.1M166.06M101.05M
Tangible asset value
145.65M141.19M143.91M172.67M105.96M
Net current asset value
133.66M129.52M133.81M159.66M74.92M
Invested capital
00000.28
Average receivables
00000
Average payables
1.83M3.15M3.29M3.4M2.75M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.39-0.49-0.48-0.38-0.68
Capex per share
-7.93-1.57-0.17-0.44-0.1

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-5.53-7.38-8.21-1.03-3.78
Operating cash flow per share
-4.43-5.34-11.15-2.050
Free cash flow per share
-4.48-5.39-11.23-2.050
Cash per share
41.1235.8524.524.3148.6
Book value per share
39.7633.9124.2723.3745.66
Tangible book value per share
39.7633.9124.2723.3745.66
Share holders equity per share
39.7633.9124.2723.3745.66
Interest debt per share
10.258.66-0.9300.17
Market cap
4.4M1.23M2.54M2.42M2.73M
Enterprise value
-23.83M-26.43M-45.99M-60.21M-153.88M
P/E ratio
-0.06-0.01-0.02-0.18-0.05
Price to sales ratio
00000
POCF ratio
-0.32-0.07-0.07-0.370
PFCF ratio
-0.31-0.07-0.07-0.370
P/B Ratio
0.040.010.030.030.02
PTB ratio
0.040.010.030.030.02
EV to sales
00000
Enterprise value over EBITDA
1.421.24-10.717.019.76
EV to operating cash flow
1.731.581.299.20
EV to free cash flow
1.711.571.289.20
Earnings yield
-3.92-18.69-10.33-1.36-5.4
Free cash flow yield
-3.18-13.65-14.13-2.70
Debt to equity
0.250.28000
Debt to assets
0.190.2000
Net debt to EBITDA
1.681.3-11.2917.79.94
Current ratio
10.227.9513.9519.4914.64
Interest coverage
-14.57.53-1.3100
Income quality
0.860.831.221.990
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.0100
Capex to revenue
00000
Capex to depreciation
-0.34-0.33-0.5800
Stock based compensation to revenue
00000
Graham number
70.3475.0466.9623.2662.3
ROIC
-0.1-0.150.040.08-0.09
Return on tangible assets
-0.11-0.16-0.31-0.04-0.08
Graham Net
28.2722.8322.6323.0445.09
Working capital
119.18M101.05M77.46M74.6M178.37M
Tangible asset value
124.03M105.96M77.46M74.6M178.38M
Net current asset value
92M74.92M77.46M74.6M177.37M
Invested capital
0.250.28000
Average receivables
0000259.5K
Average payables
2.31M2.52M1.77M946.5K1.09M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.14-0.22-0.34-0.04-0.08
Capex per share
-0.05-0.05-0.0800

MGTA Frequently Asked Questions

What is Magenta Therapeutics, Inc. stock symbol ?

Magenta Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol MGTA

What is Magenta Therapeutics, Inc. stock quote today ?

Magenta Therapeutics, Inc. stock price is $- today.

Is Magenta Therapeutics, Inc. stock public?

Yes, Magenta Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap